Recursion Pharmaceuticals, Inc.
https://www.recursion.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Recursion Pharmaceuticals, Inc.
Quantum Outperforms Classical Computer, Finding New KRAS Inhibitors
In a breakthrough for drug discovery, quantum hardware outperformed classical hardware in generating two promising KRAS inhibitors.
Moeller Looks To Prove BenevolentAI’s Doubters Wrong
The former Bayer research head needs to turn the AI-based company around, but investors are skeptical about its attempts to serve big pharma and develop its own pipeline simultaneously.
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Fewer Acquisitions And Alliances In 2023, But Valuations Increased
INFOGRAPHIC: Deal volume for both M&A and alliances fell in 2023, but average valuations rose appreciably. Antibody-drug conjugates for cancer drove high-value acquisitions and partnerships.
Company Information
- Industry
- Pharmaceuticals
-
Digital Health
- Artificial Intelligence
-
Biotechnology
-
Drug Discovery Technologies
- Bioinformatics
-
Drug Discovery Technologies
- Other Names / Subsidiaries
-
- Recursion Pharmaceuticals, LLC
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice